Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Fineline Cube Jul 10, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China

Fineline Cube Jan 10, 2023

The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...

Policy / Regulatory

NMPA Approves Expanded Production for COVID-19 Symptom Treatments

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...

Company Drug

Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review

Fineline Cube Jan 10, 2023

The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...

Company Deals

Yinjia Biosciences Raises RMB 100 Million in Series A Financing Round

Fineline Cube Jan 10, 2023

Yinjia Biosciences, a Shanghai-based developer of protein reagents and diagnostic products, has reportedly raised close...

Policy / Regulatory

China Optimizes Medical Insurance Policies for COVID-19 Treatment

Fineline Cube Jan 10, 2023

The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...

Company Deals

China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding

Fineline Cube Jan 10, 2023

China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round,...

Company Drug

Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy

Fineline Cube Jan 10, 2023

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company

Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms

Fineline Cube Jan 10, 2023

Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...

Company

Legend Biotech Receives Nasdaq Notice Regarding Listing Compliance

Fineline Cube Jan 10, 2023

Legend Biotech Corporation (NASDAQ: LEGN) announced on January 6, 2023, that it received a notice...

Company Drug

Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study

Fineline Cube Jan 9, 2023

China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...

Company Drug Policy / Regulatory

Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute

Fineline Cube Jan 9, 2023

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...

Policy / Regulatory

China Strengthens COVID-19 Prevention and Control in Rural Areas

Fineline Cube Jan 9, 2023

China has intensified its COVID-19 prevention and control measures in rural areas, with the State...

Company Drug

Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China

Fineline Cube Jan 9, 2023

The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...

Company Deals

Changzhou Sifary Medtech Secures Series B Funding for Global Expansion

Fineline Cube Jan 9, 2023

Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical...

Company Drug

Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial...

Company Drug

Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial

Fineline Cube Jan 9, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

VivaVision Biotech Partners with Everads Therapy for Retinal Disease Therapies

Fineline Cube Jan 9, 2023

China’s VivaVision Biotech Inc. has announced a collaboration agreement with Israel-based Everads Therapy Ltd to...

Company Deals

Shenzhen-Based Rhegen Bio Raises RMB 100 Million in Pre-Series B Round

Fineline Cube Jan 9, 2023

Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark

Fineline Cube Jan 9, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Posts pagination

1 … 603 604 605 … 693

Recent updates

  • PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
  • Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia
  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.